PLAU and neoplasm: Serp-1 and neuroserpin both share the capacity to inhibit uPA and tPA, and thus we postulate that the antiinflammatory/anti-tumor activity of these two proteins is secondary to inhibition of the uPA/uPA receptor (uPAR) in immune cells and/or pancreatic cancer cells.